文献速递皮肤肿瘤

实体器官移植受者免疫抑制方案与皮肤癌风险

Immunosuppressive regimens and skin cancer risk in solid-organ transplant recipients.
PubMed 文献 · Br J Dermatol · 2026-01-01

该前瞻性观察研究纳入1055例实体器官移植受者,随访3336人年,评估不同免疫抑制方案与皮肤癌风险的关系。结果显示,以mTORi为基础的方案与皮肤癌风险显著降低相关(HR 0.66,95%CI 0.47-0.92),其中依维莫司较西罗莫司更具保护性(HR 0.38,95%CI 0.21-0.69),减少剂量CNI联合mTORi在高危患者中降低37%的皮肤癌风险。

要点

  • mTORi为基础方案显著降低移植受者皮肤癌风险,依维莫司保护性优于西罗莫司。
  • 减少剂量CNI联合mTORi在高危患者中降低37%皮肤癌风险,主要驱动为鳞状细胞癌减少。
  • 高剂量CNI单药与皮肤癌风险升高相关,建议高危患者整合mTORi。

核心结论

  • 以mTORi为基础的方案,尤其是联合减少剂量他克莫司,可能为移植受者提供更安全有效的皮肤癌预防选择。

研究设计与样本

  • 西班牙Vall d'Hebron大学医院2011至2021年前瞻性观察研究,纳入1055例混合器官移植受者,随访3336人年。
  • 采用共享脆弱性Cox比例风险模型,考虑多次事件并调整时变药物暴露。

主要发现

  • 1055例受者中131例(12.4%)发生皮肤癌,共450次事件,包括317例鳞状细胞癌(70%)、118例基底细胞癌(26%)和15例黑色素瘤(3%)。
  • mTORi为基础方案与皮肤癌风险显著降低相关(HR 0.66,95%CI 0.47-0.92;P=0.01)。
  • 依维莫司较西罗莫司更具保护性(HR 0.38,95%CI 0.21-0.69;P<0.001)。
  • 减少剂量CNI联合mTORi在高危患者中降低37%皮肤癌风险(HR 0.63,95%CI 0.42-0.93;P=0.02),在移植后事件患者中降低32%(HR 0.68,95%CI 0.47-0.98;P=0.04)。
  • 风险降低主要由鳞状细胞癌发病率下降驱动。

关键数值与推荐

  • mTORi为基础方案:皮肤癌风险HR 0.66(95%CI 0.47-0.92;P=0.01)。
  • 依维莫司 vs 西罗莫司:HR 0.38(95%CI 0.21-0.69;P<0.001)。
  • 减少剂量CNI联合mTORi在高危患者中:HR 0.63(95%CI 0.42-0.93;P=0.02)。
  • 减少剂量CNI联合mTORi在移植后事件患者中:HR 0.68(95%CI 0.47-0.98;P=0.04)。

临床怎么用

  • 对于高危皮肤癌风险的实体器官移植受者,可考虑将mTORi(尤其是依维莫司)整合入免疫抑制方案。
  • 减少剂量CNI联合mTORi可能降低皮肤癌风险,尤其是鳞状细胞癌。
  • 已发生移植后皮肤恶性肿瘤的患者可从mTORi为基础方案中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Solid organ transplant recipients (SOTRs) are at increased risk of developing skin cancer due to long-term immunosuppressive (IS) therapy. Calcineurin inhibitors (CNIs), particularly tacrolimus and ciclosporin, are associated with elevated skin cancer risk. Mammalian -target of rapamycin inhibitors (mTORis) are considered protective, but real-life evidence of their effectiveness, especially when combined with reduced-dose CNIs, is limited. Understanding the impact of current IS regimens on skin cancer risk is essential for improving patient outcomes. OBJECTIVES: To evaluate the relative risk of different IS drugs and regimens on skin cancer development in SOTRs. METHODS: We conducted a prospective observational study at Vall d'Hebron University Hospital, Barcelona, Spain, from 2011 to 2021. The study included 1055 SOTRs from a mixed-organ cohort, with a combined follow-up of 3336 person-years. Real-life IS drug regimens were recorded during scheduled posttransplant screenings or dermatological follow-ups. Cox proportional hazards models with shared frailty were used to assess skin cancer risk, accounting for multiple events and adjusting for time-varying drug exposure. RESULTS: Skin cancer occurred in 131 of 1055 SOTRs (12.4%). A total of 450 skin cancer events were registered, including 317 squamous cell carcinomas (70%), 118 basal cell carcinomas (26%) and 15 melanomas (3%). mTORi-based regimens were associated with significantly lower skin cancer rates [hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.47-0.92; P = 0.01]. Everolimus appeared more protective than sirolimus (HR 0.38, 95% CI 0.21-0.69; P < 0.001). Reduced-dose CNIs combined with mTORis were linked to a 37% reduction in skin cancer rates in high-risk patients (HR 0.63, 95% CI 0.42-0.93; P = 0.02) and a 32% reduction in patients with posttransplant events (HR 0.68, 95% CI 0.47-0.98; P = 0.04). The reduction was mainly driven by decreased squamous cell carcinoma incidence. CONCLUSIONS: mTORi-based regimens, particularly with reduced-dose tacrolimus, appear to offer a safer and more effective alternative to CNI-heavy regimens for skin cancer prevention in SOTRs. Real-life data support the integration of mTORis into IS strategies to reduce skin cancer risk, particularly for high-risk patients and those who developed skin malignancies. An author video to accompany this article is available online. People who receive a solid organ transplant (SOT) need medicines to stop their immune system from rejecting the new organ. These medicines are ‘immunosuppressant’ (IS) drugs, which suppress the immune system. However, the IS drugs must be taken long term and they increase the risk of developing skin cancer. Such skin cancers can be more aggressive. We conducted a study at Vall d’Hebron University Hospital in Barcelona, Spain. We followed over 1000 people with SOTs for 10 years (2011–2021). We looked at which IS drugs, alone and combined, were best at reducing skin cancer risk. We focused on two types of drugs, ‘mTOR inhibitors’ such as everolimus and sirolimus, and ‘calcineurin inhibitors’ such as tacrolimus. We found that everolimus plus reduced-dose tacrolimus lowered skin cancer risk. Higher-dose tacrolimus alone was linked to a greater risk of skin cancers. The greatest risk reduction was for people with a high skin cancer risk or who had skin cancer after their transplant. Everolimus seemed to be more protective than sirolimus. These drug combinations could help SOT recipients who have higher skin cancer risks. Such a change could help SOT recipients reduce their skin cancer risk. This would improve their long-term health and quality of life.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Gómez-Tomás Á, González-Cruz C, García-Patos V, et al. Immunosuppressive regimens and skin cancer risk in solid-organ transplant recipients. Br J Dermatol. 2026. PMID: 41308073. doi:10.1093/bjd/ljaf483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。